www.klinickafarmakologie.cz / Klin Farmakol Farm 2022;36(1):29-33 / KLINICKÁ FARMAKOLOGIE A FARMACIE 33 PŘEHLEDOVÉ ČLÁNKY Fyzikálně-chemické vlastnosti kolistinu a jejich dopady do klinické praxe čemuž se vrací do klinického použití. Je nositelem unikátních fyzikálně-chemických vlastností, které podmiňují nejen jeho mechanismus účinku a toxicitu, ale je třeba je zohlednit i v podmínkách laboratoře či při úpravě léčiva do aplikační formy. Rizikem je vždy předčasná konverze proléčiva na kolistin a s tím související riziko nežádoucích účinků či zkreslení koncentrace analytu při terapeutickém monitorování léčiv. Terapeutickémonitorování léčiv je v případě kolistinu žádoucí modalitou, kterou lze zajistit pomocí dostupných LC-MS metod a která může pomoci zlepšit poměr benefitů a rizik spojených s podáním tohoto antibiotika. Tato práce je podpořena grantem Verification of colistin adsorption on the ECMO circuit (DSGC-2021-0179)“ v rámci projektu OP VVV“ Zkvalitnění schémat Doktorské studentské grantové soutěže a jejich pilotní implementace“, reg.č. CZ.02.2.69/0.0/0.0/19_073/0016713. LITERATURA 1. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953-1958. 2. Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015;31(4):707-721. 3. Warren HS, Kania SA, Siber GR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob Agents Chemother. 1985;28(1):107-112. 4. Velkov T, Thompson PE, Nation RL, Li J. Structure--activity relationships of polymyxin antibiotics. J Med Chem. 2010;53(5):1898-1916. 5. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob Agents Chemother. 2012;56(11):5642-5649. 6. Ehrentraut SF, Muenster S, Kreyer S et al. Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks. Microorganisms. 2020;8(3):415. 7. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004;3(1):23-28. 8. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2007;357(22):2310-2311. 9. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6(1):26. 10. Lu Q, Luo R, Bodin L et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;117(6):1335-1347. 11. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother. 2008;52(9):3047-3051. 12. Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J. Stability of colistimethate sodium in aqueous solution. Antimicrob Agents Chemother. 2012;56(12):6432-6433. 13. Bihan K, Zahr N, Becquemin MH et al. Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria. J Antimicrob Chemother. 2018;73(6):1639-1646. 14. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997;52(7):656-658. 15. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed). 1981;283(6302):1285-1287. 16. Boisson M, Jacobs M, Grégoire N et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331-7339. 17. Tsuji BT, Pogue JM, Zavascki AP et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39. 18. Colomycin. Souhrn údajů o přípravku. Státní ústav pro kontrolu léčiv [online]. [cit. 2022-01-19]. Dostupné z: https:// www.sukl.cz. 19. Abdulla A, van Leeuwen RWF, de Vries Schultink AHM. Stability of colistimethate sodium in a disposable elastomeric infusion device. Int J Pharm. 2015;486:367-369. 20. Post TE, Kamerling IMC, van Rossen RCJM et al. Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. European Journal of Hospital Pharmacy. 2018;25:337-339. 21. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis. 2005;37(2):142-145. 22. Kassamali Z, Curello J, Gregson A. Comparison of continuous versus intermittent intravenous infusion of colistimethate sodium (colistin) for treatment of carbapenem-resistant gram negative bacterial infections. 26th European Congress of Clinical Microbiology and Infectious Diseases. 2012, April 9-12. Amsterdam, Netherlands. 23. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430-3436. 24. Mohamed AF, Karaiskos I, Plachouras D et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56(8):4241-4249. 25. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30(1):143-151. 26. Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy. Chemotherapy. 2018;63(1):35-38. 27. Dudhani RV, Nation RL, Li J. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother. 2010;65(7):1412-1415. 28. Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandemmass spectrometry. Antimicrob Agents Chemother. 2010;54(5):1941-1948. 29. Hanai Y, Matsuo K, Kosugi T et al. Rapid, simple, and clinically applicable high-performance liquid chromatography method for clinical determination of plasma colistin concentrations. J Pharm Health Care Sci. 2018;4(22). 30. BinhashimNH, Alvi SN, Hammami MM. LC-MS/MS Method for Determination of Colistin in Human Plasma: Validation and Stability Studies. International Journal of Analytical Mass Spectrometry and Chromatography. 2021;9(1). 31. Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O. Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions. Antimicrob Agents Chemother. 2017;61(11):e00857-17. 32. Dagla I, Karkoula E, Baira E, Tsarbopoulos A, Gikas E. Analytical methodologies used for the determination of colistin in biological fluids. Is it still a challenge? J Pharmaceut Biomed. 2019;164:777-788. 33. Zabidi MS, Abu Bakar R, Musa N, Wan Yusuf WN. Analytical methodologies for measuring colistin levels in pharmacokinetic studies. J Liq Chromatogr Relat. 2020;43:671-686. 34. Qi B, Gijsen M, Van Brantegem P, De Vocht T, Deferm N, Abza GB, Nauwelaerts N, Wauters J, Spriet I, Annaert P. Quantitative determination of colistin A/B and colistin methanesulfonate in biological samples using hydrophilic interaction chromatography tandem mass spectrometry. Drug Test Anal. 2020;12:1183-1195. 35. Leporati M, Bua RO, Mariano F, Carignano P, Stella M, Biancone L, Vincenti M. Determination by LC–MS/MS of Colistins A and B in Plasma and Ultrafiltrate From Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. Ther Drug Monit. 2014;36(2):182-191. 36. Yuan H, Yu S, Chai G, Liu J, Zhou Q (Tony). A LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin. J Pharm Anal. 2021;11(6):732-738. 37. Peng C, Zuo S, Qiu Y, Fu S, Peng L. Determination of Colistin in Contents Derived from Gastrointestinal Tract of Feeding Treated Piglet and Broiler. Antibiotics. 2021;10(4):422. 38. BinhashimNH, Alvi SN, Hammami MM. LC-MS/MS Method for Determination of Colistin in Human Plasma: Validation and Stability Studies. Int J Anal Mass Spectrom Chromatogr. 2021;9:1-11. 39. Zhao M, Wu X-J, Fan Y-X, Guo B-N, Zhang J. Development and validation of a UHPLC–MS/MS assay for colistin methanesulphonate (CMS) and colistin in human plasma and urine using weak-cation exchange solid-phase extraction. J Pharmaceut Biomed. 2016;124:303-308. 40. Cangemi G, Barco S, Castagnola E, Tripodi G, Favata F, D’Avolio A. Development and validation of UHPLC–MS/MS methods for the quantification of colistin in plasma and dried plasma spots. J Pharmaceut Biomed. 2016;129:551-557. 41. Bihan K, Lu Q, Enjalbert M, Apparuit M, Langeron O, Rouby J-J, Funck-Brentano C, Zahr N. Determination of Colistin and Colistimethate Levels in Human Plasma and Urine by High-Performance Liquid Chromatography–Tandem Mass Spectrometry. Ther Drug Monit. 2016;38(6):796-803. 42. Gaugain M, Raynaud A, Bourcier S, Verdon E, Hurtaud- -Pessel D. Development of a liquid chromatography-tandem mass spectrometry method to determine colistin, bacitracin and virginiamycin M1 at cross-contamination levels in animal feed. Food Addit Contam A. 2021;38(9):1481-1494.
RkJQdWJsaXNoZXIy NDA4Mjc=